Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other solid neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Breast Neoplasms 27Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 13Melanoma 10Neoplasm Metastasis 9Colorectal Neoplasms 8Stomach Neoplasms 7Pancreatic Neoplasms 7Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Urogenital Neoplasms 4Multiple Myeloma 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Merkel Cell 3Prostatic Neoplasms 2Osteosarcoma 2Lymphoma 2Liver Neoplasms 2Kidney Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 2fludarabine 1epacadostat 1atezolizumab 1aldesleukin 1Nivolumab 1Interleukin-2 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × fludarabine × Breast × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡